Skip to main content
Caplight Logo









Phagos

Phagos

Private
SuresnesHealthcare & Life Scienceshttps://www.phagos.com/

Last Round

Series A

Oct 8, 2025

Total Funding Raised

$32.4M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Phagos is a biotechnology company that develops AI-driven bacteriophage therapies to combat bacterial diseases, initially focusing on animal health.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

bacteriophagephage therapyantibiotic alternativeveterinary biotechnologyprecision medicineantimicrobial resistanceAMRAI drug discoverygenomic analysistech-bioanimal healthphage cocktaillivestock healthphage-based treatmentAI-designed drugs

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Phagos Comparables

Compare Phagos with similar companies based on industry and business-model similarity.

Phagos comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Proteon Pharmaceuticals
82%
Cytophage Technologies
77%
Vetophage
74%

Phagos Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AOct 8, 2025
SeedSep 27, 2022

Key People

Founding team and executive leadership

Adèle James

Co-founder & CTO

Founding Team

Alexandros Pantalis

Co-founder & CEO

Founding Team

Ithri Benamara

CEO Associate

Executive Team

Marine Feyereisen

COO At Phagos

Executive Team

Phagos Investors

Notable investors and investment history

Phagos investors
InvestorRounds
CapHorn InvestSeries A
Hoxton VenturesSeries A, Seed
Founders CapitalSeries A
Acurio VenturesSeries A
AgFunderSeries A, Seed
Entrepreneurs FirstSeries A, Seed
Citizen CapitalSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 1, 2026

    Open roles increased to 61, 81% of headcount.

  • Jul 20, 2026

    Open roles increased to 30, 41% of headcount.

Phagos Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Phagos Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Phagos's valuation, stock price, and market status.

Firmographic Details

HeadquartersSuresnes
Employee Range75
Year Founded2021
Last FundingOct 8, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?